ES2636449T3 - Nutritional supplement - Google Patents
Nutritional supplement Download PDFInfo
- Publication number
- ES2636449T3 ES2636449T3 ES07360026.4T ES07360026T ES2636449T3 ES 2636449 T3 ES2636449 T3 ES 2636449T3 ES 07360026 T ES07360026 T ES 07360026T ES 2636449 T3 ES2636449 T3 ES 2636449T3
- Authority
- ES
- Spain
- Prior art keywords
- lactase
- amylase
- bromelama
- digestion
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01001—Alpha-amylase (3.2.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01108—Lactase (3.2.1.108)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22033—Fruit bromelain (3.4.22.33), i.e. juice bromelain
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
Suplemento alimenticio que favorece una buena ingestión y una buena digestión de proteínas animales y/o vegetales, constituido de una mezcla de enzimas constituida de amilasa, lactasa y bromelaína, siendo su dosificación ponderal la siguiente: - 15 mg a 90 mg para la amilasa; - 18 mg a 90 mg para la lactasa; y - 6 mg a 80 mg para la bromelaína.Food supplement that favors a good ingestion and a good digestion of animal and / or vegetable proteins, constituted by a mixture of enzymes made up of amylase, lactase and bromelain, being its weight dosage the following: - 15 mg to 90 mg for amylase; - 18 mg to 90 mg for lactase; and - 6 mg to 80 mg for bromelain.
Description
55
1010
15fifteen
20twenty
2525
3030
3535
4040
45Four. Five
50fifty
5555
6060
6565
DESCRIPCIONDESCRIPTION
Suplemento alimenticioNutritional supplement
La presente invencion se refiere a la digestion, a tftulo esencial de las protemas de leche, pero tambien de otras protemas absorbidas en cantidad importante y de manera repetida. Se refiere a un suplemento alimenticio que favorece una buena ingestion y una buena digestion de protemas animales y/o vegetales, y constituido de una mezcla de enzimas que comprende la amilasa, la lactasa y la bromelama.The present invention relates to the digestion, essentially as milk proteins, but also to other proteins absorbed in significant quantity and repeatedly. It refers to a nutritional supplement that favors a good ingestion and a good digestion of animal and / or vegetable proteins, and consists of a mixture of enzymes comprising amylase, lactase and bromelama.
El uso de enzimas digestivas en composiciones terapeuticas o complementos alimenticios se conoce. Por ejemplo, el documento WO2007/053619 describe una composicion para el tratamiento de la insuficiencia pancreatica de enzimas, que comprende una lipasa, una amilasa o una amiloglucosidasa y al menos una proteasa. El documento US4079125 describe una composicion para tratar los desordenes digestivos, que comprende unas enzimas pancreaticas, y el documento US5569458 describe una composicion para mejorar la absorcion de nutrimientos, que comprende vitaminas, minerales y enzimas pancreaticas.The use of digestive enzymes in therapeutic compositions or food supplements is known. For example, WO2007 / 053619 describes a composition for the treatment of pancreatic enzyme insufficiency, which comprises a lipase, an amylase or an amyloglucosidase and at least one protease. US4079125 describes a composition for treating digestive disorders, which comprises pancreatic enzymes, and US5569458 describes a composition for improving nutrient absorption, which comprises vitamins, minerals and pancreatic enzymes.
La digestion de la protema de leche plantea en particular, en numerosos casos, problemas. Asf, algunas personas no son capaces de mantener dentro de su organismo una enzima particular, la lactasa, que sirve para digerir la lactosa contenida en los productos lacteos. En realizad son intolerantes a la lactosa. Cuando estas personas consumen unos productos lacteos, sufren males tales como vomitos, hinchamientos, halitosis, calambres u otros trastornos intestinales de tipo diarrea, etc.The digestion of the milk protein poses in particular, in many cases, problems. Thus, some people are not able to maintain within their body a particular enzyme, lactase, which is used to digest the lactose contained in dairy products. In fact they are lactose intolerant. When these people consume dairy products, they suffer ills such as vomiting, swelling, halitosis, cramping or other intestinal disorders of diarrhea type, etc.
De hecho, la lactasa es deficiente en una gran parte de la poblacion adulta mundial. Esta enzima, presente en los recien nacidos para la digestion de la leche maternal, desaparece poco a poco despues del destete. Seguir consumiendo leche es como mantener la lactasa debilmente activa, pero es ir en contra de la naturaleza. Se fuerza la produccion de una enzima en principio destinada a desaparecer, de la misma manera que otras protemas absorbidas, ya sea en grandes cantidades o bien sin lfpidos y/o glucidos. Esto provoca los smtomas descritos anteriormente. La produccion insuficiente de lactasa por el organismo ademas de las consecuencias descritas anteriormente, puede tambien generar trastornos mas graves.In fact, lactase is deficient in a large part of the world's adult population. This enzyme, present in newborns for the digestion of maternal milk, disappears gradually after weaning. Continuing to consume milk is like keeping lactase weakly active, but it is against nature. The production of an enzyme in principle destined to disappear is forced, in the same way as other absorbed proteins, either in large quantities or without lipids and / or carbohydrates. This causes the symptoms described above. The insufficient production of lactase by the body in addition to the consequences described above, can also cause more serious disorders.
Por lo tanto, no basta con suplementar el organismo en lactasa para evitar los trastornos digestivos descritos anteriormente, ya que una aportacion mal dosificada en un periodo demasiado largo genera otros riesgos, por ejemplo de mala circulacion sangumea.Therefore, it is not enough to supplement the organism in lactase to avoid the digestive disorders described above, since a poorly dosed contribution in a too long period generates other risks, for example of poor blood circulation.
En referencia al problema relacionado con la digestion que resuelve la invencion, la amilasa - segundo constituyente de la invencion - es una enzima que permite en particular la digestion del almidon y de las dextrinas transformandoles en azucares reductores asimilables. Es segregada por el pancreas y las glandulas salivares. Es posible aumentar la cantidad de amilasa en el organismo cuando una u otra de estas glandulas es defectuosa.In reference to the problem related to the digestion that solves the invention, amylase - second constituent of the invention - is an enzyme that allows in particular the digestion of starch and dextrins by transforming them into assimilable reducing sugars. It is secreted by the pancreas and salivary glands. It is possible to increase the amount of amylase in the body when one or the other of these glands is defective.
Uno de sus principales beneficios en la perspectiva de favorecer la digestion es que aumenta la cantidad de saliva en la boca y permite iniciar un trabajo de reduccion de los alimentos. Evita la sensacion de “peso muerto” debido a las protemas ingeridas.One of its main benefits in the perspective of favoring digestion is that it increases the amount of saliva in the mouth and allows to start a work of food reduction. Avoid the sensation of "dead weight" due to the ingested proteins.
Una absorcion demasiado importante de amilasa lleva no obstante a un aumento anormal del porcentaje de los trigliceridos. Esto puede provocar pancreatitis cronicas, colecistitis, quistes, perforaciones de ulcera del duodeno o peritonitis, en particular en caso de absorcion de enzimas animales. Su dosificacion es por lo tanto importante.An overly important absorption of amylase leads, however, to an abnormal increase in the percentage of triglycerides. This can cause chronic pancreatitis, cholecystitis, cysts, ulcer perforations of the duodenum or peritonitis, particularly in case of absorption of animal enzymes. Its dosage is therefore important.
Todavfa en la misma perspectiva digestiva, el tercer constituyente del suplemento alimenticio de la invencion, la bromelama, conocida por otra parte y utilizada en el tratamiento de las enfermedades venosas, contusiones, artritis, poliartritis reumatoide y gota, permite tambien la reduccion total de las protemas y de sus componentes, actuando no obstante menos rapido que la lactosa y la amilasa. Por lo tanto, complementa su accion. Se utiliza tambien en Europa para favorecer el restablecimiento despues de una operacion o de heridas deportivas o para tratar sinusitis o flebitis.Still in the same digestive perspective, the third constituent of the nutritional supplement of the invention, bromelama, known on the other hand and used in the treatment of venous diseases, bruises, arthritis, rheumatoid polyarthritis and gout, also allows the total reduction of protemas and its components, acting however less fast than lactose and amylase. Therefore, it complements its action. It is also used in Europe to promote recovery after an operation or sports injuries or to treat sinusitis or phlebitis.
A altas dosis, provoca sin embargo unos efectos secundarios tales como vomitos e insuficiencia renal severa, conviene por lo tanto medir cuidadosamente su dosificacion.At high doses, however, it causes side effects such as vomiting and severe renal insufficiency, therefore it is advisable to carefully measure your dosage.
El objetivo de la presente invencion tiene como objetivo realizar un suplemento alimenticio que asegura por un lado una absorcion bucal correcta y por otro lado una digestion sin problemas, evitando sin embargo los efectos secundarios potenciales debido a sus constituyentes.The objective of the present invention aims to make a nutritional supplement that ensures on the one hand a correct oral absorption and on the other hand a smooth digestion, however avoiding the potential side effects due to its constituents.
En otras palabras, el suplemento alimenticio de la invencion debe favorecer una buena ingestion y una buena digestion de protemas animales y/o vegetales. Para este proposito, segun la invencion, la mezcla de enzimas constituida de amilasa, lactasa y bromelama, debe respetar la dosificacion ponderal siguiente:In other words, the nutritional supplement of the invention should favor a good intake and a good digestion of animal and / or vegetable proteins. For this purpose, according to the invention, the mixture of enzymes consisting of amylase, lactase and bromelain, must respect the following weight dosage:
-15 mg a 90 mg para la amilasa;-15 mg to 90 mg for amylase;
55
1010
15fifteen
20twenty
2525
3030
3535
4040
45Four. Five
50fifty
5555
6060
6565
-18 mg a 90 mg para la lactasa; y -6 mg a 80 mg para la bromelama.-18 mg to 90 mg for lactase; and -6 mg to 80 mg for bromelama.
La utilizacion de estas enzimas es principalmente interesante en la medida en la que permite acelerar las reacciones qmmicas y bioqmmicas que se producen durante la digestion. Estas enzimas tienen asf un papel de catalizador en el organismo humano.The use of these enzymes is mainly interesting in that it allows to accelerate the chemical and biochemical reactions that occur during digestion. These enzymes thus have a catalyst role in the human organism.
El suplemento alimenticio de la invencion esta indicado en caso de dificultades relacionadas con la digestion de cualquier tipo de protemas, independientemente del origen vegetal o animal de estas. Permite en primer lugar aumentar el contenido en lactasa del organismo con fines de una buena digestion, pero tambien permitir una colocacion diferente en la boca (ingestion bucal de los alimentos) asociando la lactasa con la amilasa.The nutritional supplement of the invention is indicated in case of difficulties related to the digestion of any type of protein, regardless of their plant or animal origin. It allows to increase the lactase content of the organism in the first place for the purpose of good digestion, but also to allow a different placement in the mouth (oral ingestion of food) by associating lactase with amylase.
Finalmente, la asociacion de la bromelama con la amilasa y la lactasa favorece la digestion sin efectos secundarios molestos o no deseados. La dosificacion de la lactasa es particularmente importante ya que tal dosificacion que se puede calificar de baja permite evitar unos efectos nefastos sobre la circulacion sangumea, incluso en caso de ingestion en un largo periodo. Se evitan asf los efectos secundarios, llegado el caso provocados por una alta dosificacion en lactasa.Finally, the association of bromelama with amylase and lactase favors digestion without annoying or unwanted side effects. The dosage of lactase is particularly important since such a dosage that can be described as low allows avoiding harmful effects on blood circulation, even in case of ingestion over a long period. Thus, side effects are avoided, where appropriate caused by a high dosage in lactase.
La dosificacion antes citada de la amilasa, entre 15 y 90 mg, permite tambien evitar cualquier riesgo de complicacion relacionado con una toma prolongada, aportando al mismo tiempo la contribucion explicada antes para la digestion de las protemas.The above-mentioned dosage of amylase, between 15 and 90 mg, also makes it possible to avoid any risk of complication related to prolonged intake, while contributing the contribution explained above for the digestion of the proteins.
La utilizacion de la bromelama, a razon de una cantidad comprendida entre 6 mg y 80 mg, permite aportar un beneficio significativo a la digestion y no genera ningun efecto secundario en caso de ingestion en un periodo largo.The use of bromelama, at a rate between 6 mg and 80 mg, allows a significant benefit to the digestion and does not generate any side effects in case of ingestion over a long period.
Numerosas aplicaciones del suplemento alimenticio de la invencion son posibles.Numerous applications of the nutritional supplement of the invention are possible.
Asf, segun un ejemplo, para un suplemento alimenticio destinado en particular a deportistas, las cantidades de las diferentes enzimas pueden ser mas precisamente:Thus, according to one example, for a food supplement intended in particular for athletes, the amounts of the different enzymes may be more precisely:
- 30 mg para la amilasa;- 30 mg for amylase;
- 40 mg para la lactasa; y -15 mg para la bromelama.- 40 mg for lactase; and -15 mg for bromelama.
Para otra aplicacion destinada a una utilizacion mas dietetica, las cantidades previstas son del orden de:For another application intended for a more dietary use, the expected quantities are of the order of:
- 40 mg para la amilasa;- 40 mg for amylase;
- 60 mg para la lactasa; y- 60 mg for lactase; Y
- 25 mg para la bromelama.- 25 mg for bromelama.
Segun la invencion, el suplemento alimenticio puede presentarse en cualquier forma galenica posible, a saber: polvo o granulado a rehidratar o a consumir tal cual, comprimido, pastilla, capsula, pero tambien en presentacion lfquida o pastosa. Estas formas o presentaciones no son exhaustivas.According to the invention, the food supplement can be presented in any possible Galenic form, namely: powder or granulate to be rehydrated or consumed as is, tablet, tablet, capsule, but also in liquid or pasty presentation. These forms or presentations are not exhaustive.
La invencion se refiere por otro lado a un producto alimenticio concentrado proteico y suplementado mediante un suplemento alimenticio tal como se ha presentado anteriormente. Preferentemente, dicho concentrado proteico presenta un contenido en protemas superior al 82%.The invention also relates to a protein concentrated food product and supplemented by a food supplement as presented above. Preferably, said protein concentrate has a protein content greater than 82%.
Tal producto alimenticio concentrado y suplementado permite facilitar la digestion de los alimentos hiperproteinados de cualquier tipo. Favorece secundariamente el drenaje y la eliminacion de las grasas en los deportistas, asf como el enriquecimiento de su masa muscular.Such a concentrated and supplemented food product makes it easier to digest hyperproteinated foods of any kind. Secondary favors the drainage and elimination of fats in athletes, as well as the enrichment of their muscle mass.
Permite por otro lado obtener unos resultados espectaculares para resorber las grasas en las personas obesas.It allows on the other hand to obtain spectacular results to resorb fats in obese people.
En tal producto, las protemas concentradas pueden ser de origen animal. Segun una variante, pueden tambien ser de origen vegetal, o tambien resultar de una mezcla de los dos.In such a product, the concentrated proteins can be of animal origin. According to a variant, they can also be of plant origin, or also result from a mixture of the two.
Preferentemente, segun la invencion, se utiliza la amilasa de origen vegetal y la lactasa de origen vegetal y/o animal. Segun los ensayos realizados, la asociacion de la amilasa, la lactasa y la bromelama con dosificaciones comprendidas en los intervalos indicados anteriormente, a saber 15 a 90 mg para la amilasa, 18 a 90 mg para laPreferably, according to the invention, amylase of plant origin and lactase of plant and / or animal origin are used. According to the tests carried out, the association of amylase, lactase and bromelama with dosages in the ranges indicated above, namely 15 to 90 mg for amylase, 18 to 90 mg for
lactasa, y 6 a 80 mg para la bromelama permite obtener un resultado significativo y fiable en la mejora de la digestion de las protemas. La asociacion de estas dosificaciones - que se pueden calificar de bajas - de enzimas es, por lo tanto, en contra de lo esperado, particularmente indicada en el tratamiento de las dificultades digestivas.Lactase, and 6 to 80 mg for bromelama allows to obtain a significant and reliable result in the improvement of protein digestion. The association of these dosages - which can be described as low - of enzymes is, therefore, contrary to expectations, particularly indicated in the treatment of digestive difficulties.
5 Los resultados relacionados con la asociacion de estas tres enzimas a baja dosificacion son aun mas destacables ya que su utilizacion era conocida hasta ahora solo a dosificaciones fuertes o elevadas para la obtencion de un resultado significativo en la digestion, con el riesgo de efectos secundarios molestos, incluso peligrosos en algunos casos. Los resultados particularmente interesantes obtenidos en la digestion de las protemas no pueden, en cualquier caso, ser observados con una toma de una cualquiera de las enzimas anteriores de manera individual con 10 una dosificacion tal como se ha indicado.5 The results related to the association of these three enzymes at low dosage are even more remarkable since their use was known until now only at strong or high dosages for obtaining a significant result in digestion, with the risk of annoying side effects , even dangerous in some cases. The particularly interesting results obtained in the digestion of the proteins cannot, in any case, be observed with an intake of any one of the above enzymes individually with a dosage as indicated.
Una ventaja indiscutible del suplemento alimenticio conforme a la invencion reside por lo tanto en gran parte en la interaccion de la amilasa, la lactasa y la bromelama, cada una debilmente dosificada.An unquestionable advantage of the nutritional supplement according to the invention therefore lies in large part in the interaction of amylase, lactase and bromelama, each weakly dosed.
Claims (7)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07360026.4A EP2016838B1 (en) | 2007-06-18 | 2007-06-18 | Food supplement |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2636449T3 true ES2636449T3 (en) | 2017-10-05 |
Family
ID=38645874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07360026.4T Active ES2636449T3 (en) | 2007-06-18 | 2007-06-18 | Nutritional supplement |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8846033B2 (en) |
| EP (1) | EP2016838B1 (en) |
| CA (1) | CA2707433C (en) |
| CY (1) | CY1119462T1 (en) |
| EA (1) | EA011620B1 (en) |
| ES (1) | ES2636449T3 (en) |
| LT (1) | LT2016838T (en) |
| MA (1) | MA31509B1 (en) |
| NO (1) | NO342468B1 (en) |
| PL (1) | PL2016838T3 (en) |
| PT (1) | PT2016838T (en) |
| SI (1) | SI2016838T1 (en) |
| UA (1) | UA92197C2 (en) |
| WO (1) | WO2009004238A2 (en) |
| ZA (1) | ZA201000236B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD4121C1 (en) * | 2010-09-16 | 2012-02-29 | Inst De Microbiologie Si Biotehnologie Al Academiei De Stiinte A Moldovei | Process for the production of cellulase-amylase complex |
| WO2014130007A1 (en) * | 2013-02-19 | 2014-08-28 | Deerland Enzymes, Inc. | Proteolytic compositions for rapidly and extensively degrading protein supplements |
| CN108024548B (en) * | 2015-09-21 | 2022-10-18 | 帝斯曼知识产权资产管理有限公司 | Flavorants derived from yeast cell wall |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1509866A (en) * | 1975-06-10 | 1978-05-04 | Johnson & Johnson | Enteric coated digestive enzyme compositions |
| US5902617A (en) * | 1992-05-19 | 1999-05-11 | Pabst; Patrea L. | Enzyme supplemented baby formula |
| US5260074A (en) * | 1992-06-22 | 1993-11-09 | Digestive Care Inc. | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof |
| US5569458A (en) * | 1994-09-14 | 1996-10-29 | Greenberg; Mike | Nutritional formula |
| GB2358135A (en) * | 1999-12-09 | 2001-07-18 | Finnfeeds Int Ltd | Animal feed additives comprising betaine and a protease |
| US20040253227A1 (en) * | 2002-09-11 | 2004-12-16 | Martin Kenneth A. | Perioperative multivitamin protein beverage and additive for use in preparing an individual for fast surgical recovery |
| US6900173B2 (en) * | 2002-09-11 | 2005-05-31 | Kenneth A. Martin | Perioperative multivitamin protein bar for use in preparing an individual for fast surgical recovery |
| US20050112176A1 (en) * | 2002-12-20 | 2005-05-26 | Dopson Minter H. | Nutritional supplement composition and method |
| DE20220180U1 (en) * | 2002-12-31 | 2003-04-03 | COMPLEN Vertriebs GmbH, 80804 München | Multivitamin food supplement including minerals, trace elements, fatty acids and natural materials has high vital ingredients content while showing minimal calorific loading |
| DE10321725A1 (en) * | 2003-05-14 | 2004-12-02 | Mucos Pharma Gmbh & Co | Enzyme-containing compositions, dietetic foods and pharmaceuticals made therefrom and their use for medical purposes |
| US20060115467A1 (en) * | 2004-12-01 | 2006-06-01 | Pangborn Jon B | Compositions and methods for the treatment of autism |
| US20060280840A1 (en) * | 2005-05-24 | 2006-12-14 | Robertson Marion G | Universal protein formulation meeting multiple dietary needs for optimal health and enhancing the human immune system |
| WO2007053619A2 (en) * | 2005-11-01 | 2007-05-10 | Bio-Cat, Inc. | A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency |
-
2007
- 2007-06-18 ES ES07360026.4T patent/ES2636449T3/en active Active
- 2007-06-18 PL PL07360026T patent/PL2016838T3/en unknown
- 2007-06-18 PT PT73600264T patent/PT2016838T/en unknown
- 2007-06-18 LT LTEP07360026.4T patent/LT2016838T/en unknown
- 2007-06-18 EP EP07360026.4A patent/EP2016838B1/en active Active
- 2007-06-18 SI SI200731958T patent/SI2016838T1/en unknown
-
2008
- 2008-06-16 CA CA2707433A patent/CA2707433C/en active Active
- 2008-06-16 WO PCT/FR2008/051071 patent/WO2009004238A2/en active Application Filing
- 2008-06-16 US US12/452,759 patent/US8846033B2/en active Active
- 2008-06-17 EA EA200801356A patent/EA011620B1/en unknown
- 2008-06-18 UA UAA200808227A patent/UA92197C2/en unknown
-
2010
- 2010-01-07 MA MA32488A patent/MA31509B1/en unknown
- 2010-01-12 ZA ZA201000236A patent/ZA201000236B/en unknown
- 2010-01-14 NO NO20100060A patent/NO342468B1/en not_active IP Right Cessation
-
2017
- 2017-08-30 CY CY20171100912T patent/CY1119462T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2016838T (en) | 2017-08-28 |
| WO2009004238A3 (en) | 2009-04-09 |
| MA31509B1 (en) | 2010-07-01 |
| ZA201000236B (en) | 2010-09-29 |
| EP2016838A3 (en) | 2009-08-05 |
| EP2016838B1 (en) | 2017-05-31 |
| CA2707433C (en) | 2016-04-19 |
| EP2016838A2 (en) | 2009-01-21 |
| UA92197C2 (en) | 2010-10-11 |
| US8846033B2 (en) | 2014-09-30 |
| EA011620B1 (en) | 2009-04-28 |
| US20100143320A1 (en) | 2010-06-10 |
| NO20100060L (en) | 2010-02-10 |
| PL2016838T3 (en) | 2018-01-31 |
| SI2016838T1 (en) | 2018-01-31 |
| LT2016838T (en) | 2017-11-10 |
| NO342468B1 (en) | 2018-05-28 |
| WO2009004238A2 (en) | 2009-01-08 |
| EA200801356A1 (en) | 2008-12-30 |
| CA2707433A1 (en) | 2009-01-08 |
| CY1119462T1 (en) | 2018-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2401186T3 (en) | Infant formula low in partially hydrolyzed lactose | |
| Ianiro et al. | Levothyroxine absorption in health and disease, and new therapeutic perspectives. | |
| ES2569922T3 (en) | Nutritive compositions, which include a high protein component and exogenous nucleotides | |
| ES2314485T3 (en) | COMPOSITIONS THAT INCLUDE PANTOTENIC ACID OR DERIVATIVES OF THE SAME AND ITS USE TO STIMULATE THE APPETITE. | |
| ES2636449T3 (en) | Nutritional supplement | |
| US20240108050A1 (en) | Infant nutrition with hydrolysed protein, ionic calcium and palmitic acid | |
| US20220240558A1 (en) | High-energy food supplement based on inverted sugars and ergogenic products for use in physical activity and method for producing same | |
| ES2420605T3 (en) | Nutritional fortification mixture with iron | |
| RU2012145109A (en) | METHOD FOR INCREASING TASTE ATTRACTIVENESS OF EDIBLE COMPOSITIONS | |
| ES2880602T3 (en) | Orodispersible tablet containing burlulipase and pharmaceutical composition prepared from it | |
| ES2974661T3 (en) | Blue fish protein hydrolyzate | |
| EP3232819B1 (en) | Infant nutrition with hydrolysed protein and palmitic acid | |
| ES2255653T3 (en) | GELATINE CAPSULE WITH LIPOSOLUBLE VITAMINS AND FATTY ACIDS. | |
| CA3108738A1 (en) | Compositions and methods for treatment of exocrine pancreatic insufficiency (epi) | |
| WO2013009194A1 (en) | Food supplement having high immunological value, based on a protein matrix | |
| ES2299288B1 (en) | FUNCTIONAL FOOD BASED ON A NON-FERMENTED DAIRY PRODUCT COMBINED WITH FRUIT JUICE AND CONJUGATED LINOLEIC ACID. | |
| Shukla et al. | Lactonova Happi gummy Digestive Enzymes: Helps to relief from occasional bloating & intestinal discomfort | |
| ES2296438B1 (en) | FUNCTIONAL FOOD BASED ON AN UNFERMENTED DAIRY PRODUCT AND CONJUGATED LINOLEIC ACID. | |
| BR102017021491A2 (en) | NUTRITIONAL SUPPLEMENT KIT FOR BARIATRIC SURGERY PATIENTS | |
| ES2302396A1 (en) | Functional food for prevention of overweight or obesity in humans through its regular consumption, is based on liquid fermented milk product and concentrated liquid vegetable oil rich in conjugated linoleic acid | |
| Rasmussen | 11 Nutritional Supplements | |
| Gupta | F&B SPECIALS | |
| call me Mayo | Protein+ Creatine+ L-Glutamine | |
| WO2014104871A1 (en) | Method for improving postprandial fat digestion |